|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
US20180072711A1
(en)
|
2016-09-15 |
2018-03-15 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
KR20190084063A
(ko)
|
2016-10-28 |
2019-07-15 |
이칸 스쿨 오브 메디슨 엣 마운트 시나이 |
Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
BR112019011200B1
(pt)
|
2016-12-01 |
2021-12-28 |
Arvinas Operations, Inc |
Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
KR20250117470A
(ko)
|
2016-12-23 |
2025-08-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
|
JP2020505327A
(ja)
|
2016-12-23 |
2020-02-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
BR112019015312A2
(pt)
|
2017-01-26 |
2020-03-10 |
Arvinas Operations, Inc. |
Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
|
|
IL312367A
(en)
|
2017-01-31 |
2024-06-01 |
Arvinas Operations Inc |
Cereblon ligands and bifunctional compounds comprising the same
|
|
KR102014478B1
(ko)
*
|
2017-05-12 |
2019-08-26 |
한국화학연구원 |
신규한 피페리딘-2,6-디온 유도체 및 이의 용도
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
EP4467143B1
(en)
|
2017-07-10 |
2026-03-11 |
Celgene Corporation |
Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
|
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
WO2019043217A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROBENZIMIDAZOLONES
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019148055A1
(en)
|
2018-01-26 |
2019-08-01 |
Yale University |
Imide-based modulators of proteolysis and methods of use
|
|
EP3765026A4
(en)
|
2018-03-10 |
2021-12-22 |
Yale University |
BTK PROTEOLYSIS MODULATORS AND METHODS FOR USE
|
|
EP3773576A4
(en)
|
2018-03-26 |
2021-12-29 |
C4 Therapeutics, Inc. |
Cereblon binders for the degradation of ikaros
|
|
CN111936498B
(zh)
|
2018-03-26 |
2024-04-16 |
诺华股份有限公司 |
N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
US20190300521A1
(en)
|
2018-04-01 |
2019-10-03 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
WO2019195609A2
(en)
|
2018-04-04 |
2019-10-10 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
|
IL302595A
(en)
*
|
2018-04-13 |
2023-07-01 |
Arvinas Operations Inc |
Servalon ligands and bifunctional compounds containing them
|
|
EP3781156A4
(en)
|
2018-04-16 |
2022-05-18 |
C4 Therapeutics, Inc. |
SPIROCYCLIC COMPOUNDS
|
|
FI3784663T3
(fi)
|
2018-04-23 |
2023-10-06 |
Celgene Corp |
Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
|
|
CA3099155A1
(en)
|
2018-05-14 |
2019-11-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
US12060366B2
(en)
|
2018-06-29 |
2024-08-13 |
Dana-Farber Cancer Institute, Inc. |
Bispecific degraders
|
|
EP3814330A4
(en)
*
|
2018-06-29 |
2022-07-20 |
Dana-Farber Cancer Institute, Inc. |
Immunomodulatory compounds
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
WO2020027225A1
(ja)
|
2018-07-31 |
2020-02-06 |
ファイメクス株式会社 |
複素環化合物
|
|
CN108774215A
(zh)
*
|
2018-08-15 |
2018-11-09 |
翟学旭 |
含氮杂环类衍生物及其在视网膜新生血管疾病中的应用
|
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
|
|
JP7472103B2
(ja)
|
2018-08-22 |
2024-04-22 |
クルゲン（シャンハイ），インク． |
トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法
|
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
WO2020051235A1
(en)
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
JP7323603B2
(ja)
*
|
2018-09-07 |
2023-08-08 |
メッドシャイン ディスカバリー インコーポレイテッド |
三環式縮合フラン置換ピペリジンジオン系化合物
|
|
CA3119773A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
AU2019391016B2
(en)
*
|
2018-12-03 |
2025-05-29 |
Dana-Farber Cancer Institute, Inc. |
Small molecule degraders of helios and methods of use
|
|
CN113453681B
(zh)
|
2018-12-19 |
2024-10-11 |
细胞基因公司 |
经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法
|
|
CN113473987B
(zh)
|
2018-12-19 |
2024-09-03 |
细胞基因公司 |
被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
|
|
CN120698983A
(zh)
*
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
EP3917916A4
(en)
*
|
2019-01-30 |
2022-12-14 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
EP3922632A4
(en)
*
|
2019-02-07 |
2023-02-15 |
Korea Research Institute of Chemical Technology |
DEGRADATION AGENT THAT INDUCES DEGRADATION OF A TARGET EED PROTEIN, METHOD FOR ITS MANUFACTURE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH EED, EZH2 OR PRC2 USING SUCH AGENT AS THE ACTIVE SUBSTANCE
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2020172655A1
(en)
*
|
2019-02-23 |
2020-08-27 |
New York University |
Photoswitchable protacs and synthesis and uses thereof
|
|
ES2995214T3
(en)
|
2019-03-06 |
2025-02-07 |
C4 Therapeutics Inc |
Heterocyclic compounds for medical treatment
|
|
CN120574283A
(zh)
|
2019-04-05 |
2025-09-02 |
凯麦拉医疗公司 |
Stat降解剂和其用途
|
|
WO2020206608A1
(en)
*
|
2019-04-09 |
2020-10-15 |
Ranok Therapeutics (Hangzhou) Co., Ltd. |
Methods and compositions for targeted protein degradation
|
|
WO2020214555A1
(en)
|
2019-04-16 |
2020-10-22 |
Northwestern University |
Bifunctional compounds comprising apcin-a and their use in the treatment of cancer
|
|
WO2020211822A1
(zh)
*
|
2019-04-18 |
2020-10-22 |
成都海创药业有限公司 |
一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途
|
|
JP7503851B2
(ja)
*
|
2019-05-06 |
2024-06-21 |
アイカーン スクール オブ メディスン アット マウント シナイ |
Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
|
|
CA3138197A1
(en)
|
2019-05-14 |
2020-11-19 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
WO2020251969A1
(en)
*
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020252397A1
(en)
*
|
2019-06-12 |
2020-12-17 |
Baylor College Of Medicine |
Small molecule proteolysis-targeting chimeras and methods of use thereof
|
|
WO2020263830A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3999182A1
(en)
*
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
KR20220054347A
(ko)
*
|
2019-08-26 |
2022-05-02 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
|
|
AU2020336381A1
(en)
*
|
2019-08-27 |
2022-03-03 |
The Regents Of The University Of Michigan |
Cereblon E3 ligase inhibitors
|
|
JP7209897B2
(ja)
*
|
2019-09-12 |
2023-01-20 |
メッドシャイン ディスカバリー インコーポレイテッド |
Ｃｒｂｎタンパク質モジュレーターとしての二環式化合物
|
|
JP2022547952A
(ja)
*
|
2019-09-16 |
2022-11-16 |
ノバルティス アーゲー |
Ｂｒｄ９二機能性分解誘導薬及びその使用方法
|
|
WO2021053555A1
(en)
*
|
2019-09-16 |
2021-03-25 |
Novartis Ag |
Glue degraders and methods of use thereof
|
|
JP7502425B2
(ja)
|
2019-10-01 |
2024-06-18 |
アルヴィナス・オペレーションズ・インコーポレイテッド |
Ｂｒｍ標的化化合物および関連使用方法
|
|
CA3154386A1
(en)
|
2019-10-17 |
2021-04-22 |
Michael Berlin |
Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
|
|
EP4058464A1
(en)
|
2019-11-13 |
2022-09-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN110885332B
(zh)
*
|
2019-12-06 |
2022-03-18 |
中国人民解放军第二军医大学 |
一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
GB201918414D0
(en)
*
|
2019-12-13 |
2020-01-29 |
Z Factor Ltd |
Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
JP2023507172A
(ja)
*
|
2019-12-17 |
2023-02-21 |
オリオニス バイオサイエンシズ，インコーポレイテッド |
タンパク質分解の調節
|
|
AU2020405129A1
(en)
|
2019-12-19 |
2022-06-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
KR20220119415A
(ko)
|
2019-12-20 |
2022-08-29 |
씨4 테라퓨틱스, 인코포레이티드 |
Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물
|
|
EP4081308A4
(en)
|
2019-12-23 |
2024-01-24 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
CN114829342A
(zh)
|
2019-12-23 |
2022-07-29 |
上海济煜医药科技有限公司 |
一种蛋白降解剂化合物的制备方法和应用
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
EP4090371A4
(en)
*
|
2020-01-14 |
2024-04-03 |
The Trustees of Columbia University in the City of New York |
Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases
|
|
WO2021143816A1
(zh)
*
|
2020-01-16 |
2021-07-22 |
江苏恒瑞医药股份有限公司 |
稠合酰亚胺类衍生物、其制备方法及其在医药上的应用
|
|
WO2021143822A1
(zh)
*
|
2020-01-16 |
2021-07-22 |
江苏恒瑞医药股份有限公司 |
并环酰亚胺类衍生物、其制备方法及其在医药上的应用
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
WO2021168197A1
(en)
|
2020-02-19 |
2021-08-26 |
Nurix Therapeutics, Inc. |
Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
EP4110772A4
(en)
|
2020-02-26 |
2024-04-03 |
Cullgen (Shanghai), Inc. |
TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE
|
|
EP3875456A1
(en)
*
|
2020-03-02 |
2021-09-08 |
Technische Universität Darmstadt |
Hetero-bifunctional proteolysis-targeting chimeras (protacs) for the selective degradation of fk506-binding proteins (fkbps)
|
|
CN111249276B
(zh)
*
|
2020-03-05 |
2021-07-13 |
南京巴傲得生物科技有限公司 |
吲哚布洛芬制备cbp溴区抑制试剂的用途
|
|
TW202146412A
(zh)
|
2020-03-05 |
2021-12-16 |
美商Ｃ４醫藥公司 |
用於標靶降解brd9之化合物
|
|
US20230123104A1
(en)
*
|
2020-03-06 |
2023-04-20 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Crystal of tricyclic compound acting on crbn protein and preparation method therefor
|
|
CN113387931A
(zh)
*
|
2020-03-13 |
2021-09-14 |
四川海思科制药有限公司 |
一种具有抑制或降解蛋白激酶的化合物及其制备方法和药学上的应用
|
|
EP4122925A4
(en)
*
|
2020-03-17 |
2024-04-17 |
Medshine Discovery Inc. |
Proteolysis regulator and method for using same
|
|
EP4121046A4
(en)
*
|
2020-03-18 |
2024-04-24 |
Dana-Farber Cancer Institute, Inc. |
Targeted degraders of aberrant tau based on the pet tracer pbb3
|
|
KR20230005160A
(ko)
|
2020-03-19 |
2023-01-09 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Mdm2 분해제 및 이의 용도
|
|
KR20210122163A
(ko)
*
|
2020-03-27 |
2021-10-08 |
(주) 업테라 |
Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
|
|
WO2021210878A1
(ko)
*
|
2020-04-17 |
2021-10-21 |
광주과학기술원 |
Crbn 결합 펩티드 및 이를 이용한 알츠하이머 병 예방 또는 치료용 조성물
|
|
US20240270780A1
(en)
*
|
2020-04-29 |
2024-08-15 |
Tai Bi Di Pharmaceutical Technology (Shijiazhuang) Co. Ltd |
Proteolysis targeting compound with tissue targeting capability and use thereof
|
|
CN113582974B
(zh)
*
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
WO2021231927A1
(en)
*
|
2020-05-14 |
2021-11-18 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders with a tricyclic cereblon ligand
|
|
CA3172589A1
(en)
*
|
2020-05-21 |
2021-11-25 |
Dana-Farber Cancer Institute, Inc. |
Piperidine-2,6-diones as small molecule degraders of helios and methods of use
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CR20230007A
(es)
|
2020-06-12 |
2023-06-01 |
Shanghai Jemincare Pharmaceuticals Co Ltd |
Compuesto de ftalazinona, y método de preparación y uso médico de este.
|
|
JP2023530030A
(ja)
|
2020-06-19 |
2023-07-12 |
シーフォー セラピューティクス， インコーポレイテッド |
Ｂｒａｆ分解剤
|
|
AU2021296165A1
(en)
*
|
2020-06-22 |
2022-11-24 |
Dana-Farber Cancer Institute, Inc. |
Protein tag to induce ligand dependent degradation of protein/protein-fusions
|
|
KR102559329B1
(ko)
*
|
2020-07-02 |
2023-07-25 |
포항공과대학교 산학협력단 |
신규한 프로탁 키메라 화합물, 이를 포함하는 표적 단백질 분해를 통한 질환의 예방, 개선 또는 치료용 약학적 조성물
|
|
CN115697992B
(zh)
*
|
2020-07-09 |
2025-09-19 |
西藏海思科制药有限公司 |
一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用
|
|
AU2021311245A1
(en)
*
|
2020-07-21 |
2023-03-09 |
Ubix Therapeutics, Inc. |
Compound for androgen receptor degradation, and pharmaceutical use thereof
|
|
KR20220014952A
(ko)
*
|
2020-07-29 |
2022-02-08 |
한국화학연구원 |
안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도
|
|
US20240294489A1
(en)
*
|
2020-08-03 |
2024-09-05 |
Captor Therapeutics S.A. |
Low molecular weight protein degraders and their applications
|
|
IL300397A
(en)
|
2020-08-05 |
2023-04-01 |
C4 Therapeutics Inc |
Compounds for targeted knockdown of RET
|
|
JP7591301B2
(ja)
*
|
2020-08-05 |
2024-11-28 |
リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド |
タンパク質を標的とし、分解するための化合物ならびにその調製方法および使用
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
WO2022048605A1
(zh)
*
|
2020-09-04 |
2022-03-10 |
南昌奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114163444B
(zh)
*
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
WO2022056368A1
(en)
|
2020-09-14 |
2022-03-17 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
CN114181277A
(zh)
*
|
2020-09-15 |
2022-03-15 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
EP4217352A4
(en)
|
2020-09-23 |
2024-04-10 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
|
|
CA3195695A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Astrazeneca Ab |
Compounds and their use in treating cancer
|
|
CA3194351A1
(en)
*
|
2020-10-14 |
2022-04-21 |
Christopher G. Nasveschuk |
Tricyclic compounds to degrade neosubstrates for medical therapy
|
|
JP2023547084A
(ja)
|
2020-10-21 |
2023-11-09 |
アルビナス・オペレーションズ・インコーポレイテッド |
アンドロゲン受容体タンパク質の標的分解のための化合物および方法
|
|
EP4259144A4
(en)
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
CN114621231B
(zh)
*
|
2020-12-14 |
2025-09-12 |
杭州中美华东制药有限公司 |
一种靶向降解/抑制活性的嵌合化合物及其制备方法和用途
|
|
CN116867758A
(zh)
|
2020-12-30 |
2023-10-10 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
AU2022207648A1
(en)
|
2021-01-13 |
2023-07-27 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
|
WO2022166879A1
(zh)
*
|
2021-02-04 |
2022-08-11 |
正大天晴药业集团股份有限公司 |
苯并七元环类双功能化合物及其应用
|
|
US12171768B2
(en)
|
2021-02-15 |
2024-12-24 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
EP4294790A4
(en)
*
|
2021-02-19 |
2025-02-26 |
Kymera Therapeutics, Inc. |
SMARCA DEGRADING AGENTS AND RELATED USES
|
|
WO2022195355A1
(en)
*
|
2021-03-15 |
2022-09-22 |
Novartis Ag |
Benzisoxazole derivatives and uses thereof
|
|
CN116940571A
(zh)
*
|
2021-03-15 |
2023-10-24 |
诺华股份有限公司 |
苯并异噁唑衍生物及其用途
|
|
MX2023011241A
(es)
|
2021-03-23 |
2023-10-03 |
Nuvation Bio Inc |
Compuestos dirigidos a receptores de hormonas nucleares contra el cancer.
|
|
CA3211378A1
(en)
|
2021-03-29 |
2022-10-06 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine
|
|
CN115141179B
(zh)
*
|
2021-03-31 |
2024-09-13 |
江苏恒瑞医药股份有限公司 |
一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用
|
|
CA3211149A1
(en)
*
|
2021-03-31 |
2022-10-06 |
Phillip Martin Cowley |
Pharmaceutical compound
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
KR20230171979A
(ko)
|
2021-04-16 |
2023-12-21 |
아비나스 오퍼레이션스, 인코포레이티드 |
Bcl6 단백질 분해의 조절제 및 관련 사용 방법
|
|
CN113603676B
(zh)
*
|
2021-04-28 |
2022-05-24 |
浙江工业大学 |
基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用
|
|
JP2024516024A
(ja)
*
|
2021-05-03 |
2024-04-11 |
ニューベイション・バイオ・インコーポレイテッド |
抗がん核内ホルモン受容体標的化化合物
|
|
TW202309039A
(zh)
|
2021-05-05 |
2023-03-01 |
美商百健Ｍａ公司 |
用於靶向布魯頓氏酪胺酸激酶降解之化合物
|
|
KR20240020735A
(ko)
|
2021-05-07 |
2024-02-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Cdk2 분해제 및 그 용도
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
KR102474999B1
(ko)
*
|
2021-05-26 |
2022-12-07 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
WO2022250350A1
(ko)
*
|
2021-05-26 |
2022-12-01 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
JP2024519628A
(ja)
*
|
2021-05-26 |
2024-05-21 |
イノキュア セラピューティクス インコーポレイテッド |
ピペリジンジオン誘導体
|
|
KR102489160B1
(ko)
*
|
2021-05-26 |
2023-01-18 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
WO2022255888A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
WO2022255889A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255890A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
MX2023014059A
(es)
|
2021-06-08 |
2024-03-12 |
C4 Therapeutics Inc |
Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
|
|
CN117561249A
(zh)
*
|
2021-06-25 |
2024-02-13 |
细胞基因公司 |
Cereblon结合化合物、其组合物及其用于治疗的方法
|
|
KR20240026946A
(ko)
*
|
2021-06-25 |
2024-02-29 |
셀진 코포레이션 |
세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
|
|
WO2022272061A1
(en)
*
|
2021-06-25 |
2022-12-29 |
Celgene Corporation |
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
|
|
WO2023283130A1
(en)
|
2021-07-04 |
2023-01-12 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
US20250018046A1
(en)
|
2021-07-07 |
2025-01-16 |
Biogen Ma Inc |
Compounds for targeting degradation of irak4 proteins
|
|
EP4367113A1
(en)
|
2021-07-07 |
2024-05-15 |
Biogen MA Inc. |
Compounds for targeting degradation of irak4 proteins
|
|
CA3226162A1
(en)
|
2021-07-09 |
2023-01-12 |
Plexium, Inc. |
Aryl compounds and pharmaceutical compositions that modulate ikzf2
|
|
PE20240894A1
(es)
*
|
2021-08-10 |
2024-04-24 |
Uppthera Inc |
Compuesto inductor de la degradacion de plk1 novedoso
|
|
TW202321219A
(zh)
*
|
2021-08-11 |
2023-06-01 |
大陸商四川海思科製藥有限公司 |
雜環衍生物及其組合物和藥學上的應用
|
|
CN117813307A
(zh)
|
2021-08-18 |
2024-04-02 |
新锐思生物制药股份有限公司 |
白介素-1受体相关激酶的双官能降解物及其治疗用途
|
|
CA3229646A1
(en)
*
|
2021-08-23 |
2023-03-02 |
Zhengqing YE |
Irak4 degradation agent, and preparation method therefor and use thereof
|
|
US20240365736A1
(en)
|
2021-09-01 |
2024-11-07 |
Oerth Bio Llc |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115746058A
(zh)
*
|
2021-09-03 |
2023-03-07 |
南京知和医药科技有限公司 |
一种多环化合物在制备抗肿瘤药物方面的用途
|
|
US20240409528A1
(en)
*
|
2021-10-01 |
2024-12-12 |
Dana-Farber Cancer Institute, Inc. |
Binders of cereblon and methods of use thereof
|
|
TW202322799A
(zh)
*
|
2021-10-06 |
2023-06-16 |
美商Ｃ４醫藥公司 |
冠狀病毒非結構性蛋白3降解化合物
|
|
CA3235512A1
(en)
*
|
2021-10-22 |
2023-04-27 |
Xiaobao Yang |
Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
CA3236265A1
(en)
|
2021-10-29 |
2023-05-04 |
William Leong |
Irak4 degraders and synthesis thereof
|
|
WO2023081224A1
(en)
*
|
2021-11-03 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4- yl)methyl)benzamide analogs as modulators of cereblon protein
|
|
WO2023081452A1
(en)
*
|
2021-11-05 |
2023-05-11 |
University Of South Carolina |
Small-molecule degraders of cdk8 and cdk19
|
|
WO2023088406A1
(zh)
*
|
2021-11-18 |
2023-05-25 |
正大天晴药业集团股份有限公司 |
稠合酰亚胺类衍生物
|
|
CN118574827A
(zh)
|
2021-11-24 |
2024-08-30 |
阿维纳斯运营公司 |
Brm靶向化合物和相关的使用方法
|
|
US20250059198A1
(en)
|
2021-11-24 |
2025-02-20 |
Arvinas Operations, Inc. |
Brm degrading compounds and associated methods of use
|
|
EP4438603A4
(en)
|
2021-11-25 |
2025-06-11 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
|
|
KR20240123836A
(ko)
|
2021-12-22 |
2024-08-14 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
US12122764B2
(en)
|
2021-12-22 |
2024-10-22 |
Gilead Sciences, Inc. |
IKAROS zinc finger family degraders and uses thereof
|
|
CN114085213B
(zh)
*
|
2022-01-20 |
2022-03-25 |
苏州国匡医药科技有限公司 |
一种arv-471的制备方法
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
CA3243560A1
(en)
|
2022-01-31 |
2023-08-03 |
Kymera Therapeutics, Inc. |
Iraqi Degradation Agents and Their Uses
|
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
US20250205344A1
(en)
*
|
2022-03-24 |
2025-06-26 |
Glaxosmithkline Intellectual Property Development Limited |
2,4-dioxotetrahydropyrimidinyl deratives as degrons in protacs
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
WO2023212599A2
(en)
*
|
2022-04-26 |
2023-11-02 |
Endotarget Inc. |
Compounds and methods for targeted degradation of estrogen receptors
|
|
CA3249074A1
(en)
|
2022-06-06 |
2023-12-14 |
C4 Therapeutics, Inc. |
BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS
|
|
AU2023300784A1
(en)
*
|
2022-06-30 |
2025-01-02 |
Anhorn Medicines Co., Ltd. |
Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related diseases by using the same
|
|
KR20250028371A
(ko)
|
2022-07-01 |
2025-02-28 |
길리애드 사이언시즈, 인코포레이티드 |
Cd73 화합물
|
|
US20260028354A1
(en)
*
|
2022-07-12 |
2026-01-29 |
Regent Of The University Of Michigan |
Tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
CN116496253B
(zh)
*
|
2022-08-19 |
2024-10-11 |
中国人民解放军军事科学院军事医学研究院 |
c-MET蛋白靶向降解剂及其医药应用
|
|
CN115089588A
(zh)
*
|
2022-08-22 |
2022-09-23 |
云南大学 |
达沙布韦作为e3连接酶新型配体构建protac的应用
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
WO2024054591A1
(en)
|
2022-09-07 |
2024-03-14 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024054955A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024054954A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024054953A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
CN118019736A
(zh)
*
|
2022-09-08 |
2024-05-10 |
标新生物医药科技(上海)有限公司 |
基于cereblon蛋白设计的分子胶化合物及其应用
|
|
EP4584259A1
(en)
|
2022-09-09 |
2025-07-16 |
Innovo Therapeutics, Inc. |
Ck1alpha and dual ck1alpha / gspt1 degrading compounds
|
|
US20260098043A1
(en)
*
|
2022-09-14 |
2026-04-09 |
Hainan Simcere Zaiming Pharmeceutical Co., Ltd. |
Polycyclic compound and use thereof
|
|
WO2024064316A1
(en)
|
2022-09-23 |
2024-03-28 |
Regents Of The University Of Michigan |
Compounds and compositions as smarca2/4 inhibitors and uses thereof
|
|
WO2024073475A1
(en)
*
|
2022-09-27 |
2024-04-04 |
Oncopia Therapeutics, Inc. D/B/A Proteovant Therapeutics, Inc. |
Cereblon ligands and uses thereof
|
|
JP2025533592A
(ja)
*
|
2022-09-29 |
2025-10-07 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
テトラリン系誘導体の薬学的に許容される塩、結晶型及び調製方法
|
|
CN119998300A
(zh)
*
|
2022-09-29 |
2025-05-13 |
海南先声再明医药股份有限公司 |
一类稠环化合物及其用途
|
|
CN117801051A
(zh)
*
|
2022-09-30 |
2024-04-02 |
苏州德亘生物医药有限公司 |
一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
|
|
JP2026500894A
(ja)
|
2022-10-24 |
2026-01-09 |
アルヴィナス・オペレーションズ・インコーポレイテッド |
アンドロゲン受容体の標的分解のための化合物及び方法
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
KR20240075764A
(ko)
*
|
2022-11-22 |
2024-05-29 |
주식회사 이노큐어테라퓨틱스 |
cMET 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물
|
|
KR20240076746A
(ko)
*
|
2022-11-22 |
2024-05-30 |
주식회사 이노큐어테라퓨틱스 |
Brd 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물
|
|
EP4624472A1
(en)
*
|
2022-11-22 |
2025-10-01 |
Innocure Therapeutics, Inc. |
Degrader including novel c-met protein ligand and pharmaceutical composition including same
|
|
WO2024123195A1
(en)
*
|
2022-12-06 |
2024-06-13 |
Captor Therapeutics S.A. |
Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
KR20250130610A
(ko)
*
|
2022-12-06 |
2025-09-02 |
캡터 테라퓨틱스 에스.에이. |
유비퀴틴 리가제 및 표적 mcl-1 단백질에 결합하는 이작용성 화합물을 사용하는 표적화된 단백질 분해
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
TWI882643B
(zh)
*
|
2023-01-16 |
2025-05-01 |
大陸商南京明德新藥研發有限公司 |
取代的苯並七元環化合物及其應用
|
|
US12448399B2
(en)
|
2023-01-26 |
2025-10-21 |
Arvinas Operations, Inc. |
Cereblon-based KRAS degrading PROTACs and uses related thereto
|
|
KR20250145679A
(ko)
*
|
2023-02-16 |
2025-10-13 |
브리스톨-마이어스 스큅 컴퍼니 |
Ret 키나제의 분해제로서의 이소인돌리논 글루타르이미드 및 페닐 글루타르이미드 유사체
|
|
CN116253719B
(zh)
*
|
2023-03-06 |
2025-04-01 |
苏州国匡医药科技有限公司 |
一种雌激素和雄激素受体双重降解剂及其应用
|
|
TW202508568A
(zh)
|
2023-04-07 |
2025-03-01 |
瑞典商阿斯特捷利康公司 |
Ｉｒａｋ４蛋白水解靶向嵌合體
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20250173569A
(ko)
*
|
2023-04-20 |
2025-12-10 |
오론 세러퓨틱스 인코포레이티드 |
세포 상태 표적화 기술
|
|
CR20250446A
(es)
|
2023-04-21 |
2025-12-02 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
PE20252789A1
(es)
|
2023-05-24 |
2025-12-22 |
Kumquat Biosciences Inc |
Compuestos heterociclicos y usos de estos
|
|
EP4722207A1
(en)
*
|
2023-06-01 |
2026-04-08 |
Gluetacs Therapeutics (Shanghai) Co., Ltd. |
Oxoisoindolinyl-substituted tetrahydropyrimidinedione derivative and use thereof
|
|
CN120202200A
(zh)
*
|
2023-06-01 |
2025-06-24 |
标新生物医药科技(上海)有限公司 |
基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
|
|
CN121263412A
(zh)
*
|
2023-06-01 |
2026-01-02 |
上海海和药物研究开发股份有限公司 |
用于雄激素受体依赖性疾病的苯并(杂)环烷基化合物
|
|
PE20260307A1
(es)
|
2023-06-14 |
2026-02-11 |
Astrazeneca Ab |
Degradadores de smarca2 y usos de estos
|
|
PE20260301A1
(es)
|
2023-06-14 |
2026-02-10 |
Astrazeneca Ab |
Derivados de 3-[3-amino-6-(2-hidroxifenil)piridazin-4-il]-3,8-diazabiciclo[3.2.1]octano como protacs degradantes de smarca2 para el tratamiento del cancer
|
|
EP4731611A1
(en)
*
|
2023-06-23 |
2026-04-29 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Targeted degraders of hiv-1 nef for the treatment of hiv disease
|
|
CN121263417A
(zh)
|
2023-06-30 |
2026-01-02 |
金橘生物科技公司 |
取代的稠合三环胺化合物及其作为ras抑制剂的用途
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
EP4735452A2
(en)
|
2023-06-30 |
2026-05-06 |
Merck Patent GmbH |
Heterobifunctional compounds for the degradation of kras protein
|
|
EP4735438A2
(en)
|
2023-06-30 |
2026-05-06 |
Merck Patent GmbH |
Heterobifunctional compounds for the degradation of kras
|
|
WO2025011623A1
(zh)
*
|
2023-07-12 |
2025-01-16 |
上海壹迪生物技术有限公司 |
氰基喹啉类靶向蛋白降解分子、其制备方法和应用
|
|
CN121620513A
(zh)
|
2023-07-26 |
2026-03-06 |
吉利德科学公司 |
Parp7抑制剂
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
CN121773112A
(zh)
|
2023-08-17 |
2026-03-31 |
海思科医药集团股份有限公司 |
一种氰基芳香环衍生物及其在医药上的应用
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025056074A1
(zh)
*
|
2023-09-14 |
2025-03-20 |
中国科学院上海药物研究所 |
杂环基取代的吲唑酮类化合物、其制备方法、药物组合物及其应用
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
TW202530192A
(zh)
|
2023-09-22 |
2025-08-01 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
新穎化合物
|
|
TW202530189A
(zh)
|
2023-09-29 |
2025-08-01 |
日商第一三共股份有限公司 |
３－苯基丙基胺衍生物
|
|
WO2025075693A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Purdue Research Foundation |
Shp2 degraders for cancer therapy
|
|
AU2024374420A1
(en)
|
2023-11-02 |
2026-04-16 |
Kumquat Biosciences Inc. |
Degraders and uses thereof
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025114875A1
(en)
*
|
2023-12-01 |
2025-06-05 |
Astrazeneca Ab |
Er degraders and uses thereof
|
|
WO2025136129A1
(en)
*
|
2023-12-22 |
2025-06-26 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target protein kinase c
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025188857A1
(en)
*
|
2024-03-05 |
2025-09-12 |
University Of Florida Research Foundation, Incorporated |
Hdac8 degraders and uses thereof
|
|
TW202543650A
(zh)
|
2024-03-08 |
2025-11-16 |
美商海爾達醫療運營公司 |
異雙官能化合物及其在治療疾病中之用途
|
|
WO2025212557A1
(en)
*
|
2024-04-01 |
2025-10-09 |
The Johns Hopkins University |
Delivery of aurora kinase inhibitors using nano-scale drug delivery platforms by covalent conjugation
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026005533A1
(ko)
*
|
2024-06-27 |
2026-01-02 |
한미약품 주식회사 |
신규한 이종이작용기 단백질 분해제 및 이의 용도
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN119241498B
(zh)
*
|
2024-09-26 |
2026-04-07 |
天津科技大学 |
一种具有抗mash活性的acly靶向protac嵌合体、方法和应用
|